Emerging role of botulinum toxin in the management of voiding dysfunction

Journal of Urology

Volumn 171, Issue 6 I, 2004, Pages 2128-2137

  Smith, Christopher P ^a   Chancellor, Michael B ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Bladder, neurogenic; Botulinum toxins; Cystitis, interstitial; Urethra drug effects; Urinary incontinence drug therapy

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B;

BLADDER DISEASE; BLADDER SPHINCTER; BOTULISM; CLINICAL TRIAL; DETRUSOR DYSSYNERGIA; ERECTILE DYSFUNCTION; HEART BLOCK; HUMAN; HYPERREFLEXIA; INTERSTITIAL CYSTITIS; MEDICAL LITERATURE; MEDLINE; MICTURITION DISORDER; MULTICENTER STUDY; MUSCLE WEAKNESS; NEUROGENIC BLADDER; OVERACTIVE BLADDER; PARALYSIS; PELVIS FLOOR; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RESIDUAL URINE; REVIEW; STRESS INCONTINENCE; SYSTEMIC DISEASE; URETHRA DISEASE; URINE INCONTINENCE; URINE RETENTION; UROLOGY;

EID: 2442551736     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000127725.48479.89     Document Type: Review

References (89)

1. van Ermengem, E.: Ueber einen neuen anaeroben Bacillus and seine Beziehungen zum Botulisms. Ztsch Hyg Infekt, 26: 1, 1897
2. Arnon, S. S., Schechter, R., Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S. et al: Botulinum toxin as a biological weapon: medical and public health management. JAMA, 285: 1059, 2001
3. Schurch, B., Hauri, D., Rodic, B., Curt, A., Meyer, M. and Rossier, A. B.: Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol, 155: 1023, 1996
4. Petit, H., Wiart, E., Gaujard, E., LeBreton, F., Ferriere, J. M., Lagueny, A. et al: Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease. Spinal Cord, 36: 91, 1998
5. Dykstra, D. D. and Sidi, A.: Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil, 71: 24, 1990
6. Dykstra, D. D., Sidi, A. A., Scott, A. B., Pagel, J. M. and Goldish, G. D.: Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol, 139: 919, 1988
7. Schurch, B., Stöhrer, M., Kramer, G., Schmid, D. M., Gaul, G. and Hauri, D.: Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol, 164: 692, 2000
8. Chancellor, M. B. and Smith, C. P.: One surgeon's experience in 50 patients with botulinum toxin injection into the bladder and urethra. J Urol, suppl., 167: 249, abstract 981, 2002
9. O'Leary, M., Erickson, J., Smith, C. and Chancellor, M.: Botulinum toxin urethral sphincter injection restores spontaneous micturition in multiple sclerosis women. J Urol, suppl., 167: 273, abstract 1074, 2002
10. Smith, C. P., Radziszewski, P., Majewski, M., Borkowski, A., Boone, T. B. and Chancellor, M. B.: Botulinum toxin A improves voiding and pain indices in patients with interstitial cystitis: a case series. Presented at annual meeting of American Urological Association, Society for Urodynamics and Female Urology, Chicago, Illinois, April 26-May 1, 2003
11. Smith, C. P., Franks, M. E., McNeil, B. K., Ghosh, R., de Groat, W. C., Chancellor, M. B. et al: Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol, 169: 1896, 2003
12. Dickson, E. C.: Botulism. A clinical and experimental study. Rockefeller Inst Med Res Monogr, 8: 1, 1918
13. DasGupta, B. R.: Structures of botulinum neurotoxin, its functional domains, and perspectives on the crystalline type A toxin. In: Therapy With Botulinum Toxin. Edited by J. Jankovic and M. Hallet. New York: Marcel Dekker, pp. 15-39, 1994
14. Schiavo, G., Rossetto, O., Santucci, A., DasGupta, B. R. and Montecucco, C.: Botulinum neurotoxins are zinc proteins. J Biol Chem, 267: 23479, 1992
15. Barinaga, M.: Secrets of secretion revealed. Science, 260: 487, 1993
16. Schiavo, G., Santucci, A., Dasgupta, B. R., Mehta, P. P., Jontes, J., Benfenati, F. et al: Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett, 335: 99, 1993
17. Lew, M. F.: Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction. Clin J Pain, suppl., 18: S142, 2002
18. Scott, A. B. and Suzuki, D.: Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord, 3: 333, 1988
19. Malnick, S. D., Metchnik, L., Somin, M., Bergman, N. and Attali, M.: Fatal heart block following treatment with botulinum toxin for achalasia. Am J Gastroenterol, 95: 3333, 2000
20. Kessler, K. R., Skutta, M. and Benecke, R.: Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol, 246: 265, 1999
21. Del Popolo, G.: Botulinum-A toxin in the treatment of detrusor hyperreflexia. Neurourol Urodyn, 20: 522, 2001
22. Wyndaele, J. J. and Van Dromme, S. A.: Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord, 40: 599, 2002
23. Sautter, T., Herzog, A., Hauri, D. and Schurch, B.: Transient paralysis of the bladder due to wound botulism. Eur Urol, 39: 610, 2001
24. Papadonikolakis, A. S., Vekris, M. D., Kostas, J. P., Korompilias, A. V. and Soucacos, P. N.: Transient erectile dysfunction associated with intramuscular injection of botulinum toxin type A. J South Orthop Assoc, 11: 116, 2002
25. Schnider, P., Berger, T., Schmied, M., Fertl, L. and Auff, E.: Increased residual urine volume after local injection of botulinum A toxin. Nervenarzt, 66: 465, 1995
26. Khurana, V., Nehme, O., Khurana, R. and Barkin, J. S.: Urinary retention secondary to detrusor muscle hypofunction after botulinum toxin injection for achalasia. Am J Gastroenterol, 96: 3211, 2001
27. Kim, H. S., Hwang, J. H., Jeong, S. T., Lee, Y. T., Lee, P. K., Suh, Y. L. et al: Effect of muscle activity and botulinum toxin dilution volume on muscle paralysis. Dev Med Child Neurol, 45: 200, 2003
28. Dolimbek, B. Z., Jankovic, J. and Atassi, M. Z.: Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response. Immunol Invest, 31: 247, 2002
29. Rosenberg, J. S., Middlebrook, J. L. and Atassi, M. Z.: Localization of the regions on the C-terminal domain of the heavy chain of botulinum A recognized by T lymphocytes and by antibodies after immunization of mice with pentavalent toxoid. Immunol Invest, 26: 491, 1997
30. Goschel, H., Wohlfarth, K., Frevert, J., Dengler, R. and Bigalke, H.: Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies-therapeutic consequences. Exp Neurol, 147: 96, 1997
31. Greene, P. E. and Fahn, S.: Response to botulinum toxin F in seronegative botulinum toxin A-resistant patients. Mov Disord, 11: 181, 1996
32. Jankovic, J. and Schwartz, K.: Response and immunoresistance to botulinum toxin injections. Neurology, 45: 1743, 1995
33. Jankovic, J., Vuong, K. D. and Ahsan, J.: Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology, 60: 1186, 2003
34. Brin, M. F.: Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve, suppl., 6: S146, 1997
35. Lapides, J., Diokno, A. C., Silber, S. J. and Lowe, B. S.: Clean, intermittent self-catheterization in the treatment of urinary tract disease. Trans Am Assoc Genitourin Surg, 63: 92, 1971
36. Koyanagi, T., Morita, H., Takamatsu, T., Taniguchi, K. and Shinno, Y.: Radical transurethral resection of the prostate in male paraplegics revisited: further clinical experience and urodynamic considerations for its effectiveness. J Urol, 137: 72, 1987
37. Chancellor, M. B., Gajewski, J., Ackman, C. F. D., Appell, R. A., Bennett, J., Binard, J. et al: Long-term followup of the North American Multicenter UroLume Trial for the treatment of external detrusor-sphincter dyssynergia. J Urol, 161: 1545, 1999
38. Chancellor, M. B., Bennett, C., Simoneau, A. R., Finocchiaro, M. V., Kline, C., Bennett, J. K. et al: Sphincteric stent versus external sphincterotomy in spinal cord injured men: prospective randomized multicenter trial. J Urol, 161: 1893, 1999
39. Gajewski, J. B., Chancellor, M. B., Ackman, C. F. D., Appell, R. A., Bennett, J., Binard, J. et al: Removal of UroLume endoprosthesis: experience of the North American Study Group for detrusor sphincter dyssynergia application. J Urol, 163: 773, 2000
40. McFarlane, I. P., Foley, S. J. and Shah, P. J.: Long-term outcome of permanent urethral stents in the treatment of detrusor-sphincter dyssynergia. Br J Urol, 78: 729, 1996
41. Borodic, G. E., Joseph, M., Fay, L., Cozzolino, D. and Ferrante, R. J.: Botulinum A toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. Head Neck, 12: 392, 1990
42. Mall, V., Glocker, F. X., Frankenschmidt, A., Gordjani, N., Heinen, F., Brandis, M. et al: Treatment of neuropathic bladder using botulinum toxin A in a 1-year old child with myelomeningocele. Pediatr Nephrol, 16: 1161, 2001
43. de Seze, M., Petit, H., Gallien, P., de Seze, M. P., Joseph, P. A., Mazaux, J. M. et al: Botulinum A toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol, 42: 56, 2002
44. Gallien, P., Robineau, S., Verin, M., Le Bot, M.-P., Nicolas, B. and Brissot, R.: Treatment of detrusor sphincter dyssynergia by transperineal injection of botulinum toxin. Arch Phys Med Rehabil, 79: 715, 1998
45. Phelan, M. W., Franks, M., Somogyi, G. T., Yokoyama, T., Fraser, M. O., Lavelle, J. P. et al: Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol, 165: 1107, 2001
46. Schurch, B., Hodler, J. and Rodie, B.: Botulinum A toxin as a treatment of detrusor-sphincter dyssynergia in patients with spinal cord injury: MRI controlled transperineal injections. J Neurol Neurosurg Psychiatry, 63: 474, 1997
47. McGuire, E. J., Woodside, J. R., Borden, T. A. and Weiss, R. M.: Prognostic value of urodynamic testing in myelodysplastic patients. J Urol, 126: 205, 1981
48. Kim, Y. H., Kattan, M. W. and Boone, T. B.: Bladder leak point pressure: the measure for sphincterotomy success in spinal cord injured patients with external detrusor-sphincter dyssynergia. J Urol, 159: 493, 1998
49. Kuo, H.: Effect of botulinum A toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology, 61: 550, 2003
50. Smith, C. P., O'Leary, M., Erickson, J., Somogyi, G. T. and Chancellor, M. B.: Botulinum toxin urethral sphincter injection resolves urinary retention after pubovaginal sling operation. Int Urogynecol J Pelvic Floor Dysfunct, 13: 185, 2002
51. FitzGerald, M. P. and Brubaker, L.: The etiology of urinary retention after surgery for genuine stress incontinence. Neurourol Urodyn, 20: 13, 2001
52. Fowler, C. J., Betts, C. D., Christmas, T. J., Swash, M. and Fowler, C. G.: Botulinum toxin in the treatment of chronic urinary retention in women. Br J Urol, 70: 387, 1992
53. Zermann, D., Ishigooka, M., Schubert, J. and Schmidt, R. A.: Perisphincteric injection of botulinum toxin type A. A treatment option for patients with chronic prostatic pain? Eur Urol, 38: 393, 2000
54. Mackenzie, I., Burnstock, G. and Dolly, J. O.: The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience, 7: 997, 1982
55. Kim, H. J., Seo, K., Yum, K. W., Oh, Y. S., Yoon, T. G. and Yoon, S. M.: Effects of botulinum toxin type A on the superior cervical ganglia in rabbits. Auton Neurosci, 102: 8, 2002
56. Morris, J. L., Jobling, P. and Gibbins, I. L.: Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons. Am J Physiol Heart Circ Physiol, 281: H2124, 2001
57. Ishikawa, H., Mitsui, Y., Yoshitomi, T., Mashimo, K., Aoki, S., Mukono, K. et al: Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Nippon Ganka Gakkai Zasshi, 105: 218, 2001
58. Doggweiler, R., Zermann, D.-H., Ishigooka, M. and Schmidt, R. A.: Botox-induced prostatic involution. Prostate, 37: 44, 1998
59. Lange, D. J., Brin, M. F., Warner, C. L., Fahn, S. and Lovelace, R. E.: Distant effects of local injection of botulinum toxin. Muscle Nerve, 10: 552, 1987
60. Aoki, K. R.: Immunologic and other properties of therapeutic botulinum toxin serotypes. In: Scientific and Therapeutic Aspects of Botulinum Toxin. Edited by M. F., Brin, J. Jankovic and M. Hallet. Philadelphia: Lippincott Williams & Wilkins, vol. 9, p. 103, 2002
61. Chancellor, M. B. and de Groat, W. C.: Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J Urol, 162: 3, 1999
62. Stohrer, M., Schurch, B., Kramer, G., Schmid, D., Gaul, G. and Hauri, D.: Botulinum A-toxin in the treatment of detrusor hyperreflexia in spinal cord injured patients: A new alternative to medical and surgical procedures? Neurourol Urodyn, 18: 401, 1999
63. Schurch, B., Stöhrer, M., Kramer, G., Grosse, J., Schmid, D. and Hauri, D.: Botulinum toxin-A to treat detrusor hyperreflexia in spinal cord injured patients. Neurourol Urodyn, 20: 521, 2001
64. Reitz, A., Stöhrer, M., Kramer, G., Del Popolo, G., Chartier-Kastler, E., Panneck, J. et al: European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for neurogenic incontinence. J Urol, suppl., 169: 373, abstract 1393, 2003
65. Grosse, J. O., Kramer, G., Löchner-Ernst, D. and Stöhrer, M.: Outcome of repeat detrusor injections of botulinum A toxin (BTX-A) for severe neurogenic detrusor overactivity and incontinence. J Urol, suppl., 169: 373, abstract 1394, 2003
66. Schulte-Baukloh, H., Michael, T., Schobert, J., Stolze, T. and Knispel, H. H.: Efficacy of botulinum-A toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology, 59: 325, 2002
67. Radziszewski, P., Dobronski, P. and Borkowski, A.: Treatment of the non-neurogenic storage and voiding disorders with the chemical denervation caused by botulinum toxin type A - A pilot study. Neurourol Urodyn, 20: 410, 2001
68. Zermann, D. H., Ishigooka, M., Schubert, J. and Schmidt, R. A.: Trigonum and bladder base injection of botulinum toxin A (BTX) in patients with severe urgency-frequency-syndrome refractory to conservative medical treatment and electrical stimulation. Neurourol Urodyn, 20: 412, 2001
69. Loch, A., Loch, T., Osterhage, J., Alloussi, S. and Stöckle, M.: Botulinum-A toxin detrusor injections in the treatment of non-neurologic and neurologic cases of urge incontinence. J Urol, suppl., 169: 124, abstract 481, 2003
70. Chancellor, M. B., O'Leary, M., Erickson, J., Cannon, T. W., Chermansky, C., Leng, W. W. et al: Successful use of bladder botulinum toxin injection to treat refractory overactive bladder. J Urol, suppl., 169: 351, abstract DP50, 2003
71. Carpenter, F. G.: Motor responses of the urinary bladder and skeletal muscle in botulinum intoxicated rates. J Physiol, 188: 1, 1967
72. Bigalke, H. and Habermann, E.: Blockade by tetanus and botulinum A toxin of postganglionic cholinergic nerve endings in the myenteric plexus. Naunyn Schmiedebergs Arch Pharmacol, 312: 255, 1980
73. Shimazaki, Y., Nishiki, T., Omori, A., Sekiguchi, M., Kamata, Y., Kozaki, S. et al: Phosphorylation of 25-kDa Synaptosome-associated protein. Possible involvement in protein kinase C-mediated regulation of neurotransmitter disease. J Biol Chem, 271: 14548, 1996
74. Nakov, R., Habermann, E., Hertting, G., Wurster, S. and Allgaier, S.: Effects of botulinum A toxin on presynaptic modulation of evoked transmitter release. Eur J Pharmacol, 164: 45, 1989
75. Somogyi, G. T., Zernova, G. V., Yoshiyama, M., Yamamoto, T. and de Groat, W. C.: Frequency dependence of muscarinic facilitation of transmitter release in urinary bladder strips from neurally intact or chronic spinal cord transected rats. Br J Pharmacol, 125: 241, 1998
76. Aoki, K. R.: Pharmacology and immunology of botulinum toxin serotypes. J Neurol, suppl., 248: 3, 2001
77. Smith, C. P., Boone, T. B., de Groat, W. C., Chancellor, M. B. and Somogyi, G. T.: Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions. Brain Res Bull, 61: 165, 2003
78. Tsui, J. K., Eisen, A., Stoessl, A. J., Calne, S. and Calne, D. B.: Double-blind study of botulinum toxin in spasmodic torticollis. Lancet, 2: 245, 1986
79. Cheshire, W. P., Abashian, S. W. and Mann, J. D.: Botulinum toxin in the treatment of myofascial pain syndrome. Pain, 59: 65, 1994
80. Silberstein, S., Mathew, N., Saper, J. and Jenkins, S.: Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache, 40: 445, 2000
81. Welch, M. J., Purkiss, J. R. and Foster, K. A.: Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon, 38: 245, 2000
82. Purkiss, J. R., Welch, M. J., Doward, S., Foster, K. A. and Quinn, C. P.: A method for the measurement of [3H]-glutamate release from cultured dorsal root ganglion neurons. Biochem Soc Trans, 26: S108, 1998
83. Cui, M. and Aoki, K. R.: Botulinum toxin type A (BTX-A) reduces inflammatory pain in the rat formalin model. Cephalalgia, 20: 414, 2000
84. Smith, C. P., Fraser, M. O., Bartho, L., Degroat, W. C., Chancellor, M. B. and Somogyi, G. T.: Botulinum toxin A inhibits afferent nerve evoked bladder strip contractions. J Urol, suppl., 167: 41, abstract 164, 2002
85. Cayan, S., Coskun, B., Bozlu, M., Acar, D., Akbay, E. and Ulusoy, E.: Botulinum toxin type A may improve bladder function in a rat chemical cystitis model. Urol Res, 30: 399, 2003
86. Maria, G., Destito, A., Lacquaniti, S., Bentivoglio, A. R., Brisinda, G. and Albanese, A.: Relief by botulinum toxin of voiding dysfunction due to prostatitis. Lancet, 352: 625, 1998
87. Blersch, W., Schulte-Mattler, W. J., Przywara, S., May, A., Bigalke, H. and Wohlfarth, K.: Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study. J Neurol Sci, 205: 59, 2002
88. Kramer, H. H., Angerer, C., Erbguth, F., Schmelz, M. and Birklein, F.: Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol, 250: 188, 2003
89. Maria, G., Brisinda, G., Civello, I. M., Bentivoglio, A. R., Sganga, G. and Albanese, A.: Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology, 62: 259, 2003